Crinetics Pharmaceuticals(US:CRNX) Newsfilter·2024-06-18 20:30Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [1][13] - The company was founded in 2008 with a vision to transform the treatment of endocrine diseases [1] Lead Drug Candidate - The lead drug candidate, paltusotine, is on track for a New Drug Application submission with the U.S. Food and Drug Administration (FDA) by the end of 2024 [1] - Paltusotine is a first-in-class, oral somatostatin receptor type 2 (SST2) agonist currently in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors [13] Pipeline and Drug Development - Crinetics has a deep pipeline of internally discovered drug candidates, including atumelnant (CRN04894), an oral ACTH antagonist completing Phase 2 clinical studies for congenital adrenal hyperplasia and Cushing's disease [13] - The company is also developing treatments for various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity [13] Leadership Recognition - Scott Struthers, Ph.D., founder and CEO of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner, recognizing his leadership and the company's growth [14][15] - As a regional award winner, Dr. Struthers is eligible for the National Awards, with winners announced in November at the Strategic Growth Forum® [15]